Secukinumab

Secukinumab
Autoinjector with Cosentyx by Novartis (Secukinumab)
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetIL17A
Clinical data
Trade namesCosentyx
Other namesAIN457
AHFS/Drugs.comMonograph
MedlinePlusa615011
License data
Pregnancy
category
  • AU: C
Routes of
administration		Subcutaneous, intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6584H10134N1754O2042S44
Molar mass147944.37 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis.[4][5][6] It binds to the protein interleukin (IL)-17A and is marketed by Novartis.[4][5][6]

  1. ^ "Cosentyx (Novartis Pharmaceuticals Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 7 October 2022. Archived from the original on 22 November 2022. Retrieved 9 April 2023.
  2. ^ "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
  3. ^ "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Archived from the original on 20 February 2020. Retrieved 7 April 2024.
  4. ^ a b c "Cosentyx 150mg and 300mg solution for injection in pre-filled syringe and pre-filled pen - Summary of Product Characteristics (SmPC)". (emc). 6 June 2022. Archived from the original on 3 October 2017. Retrieved 9 November 2022.
  5. ^ a b c "Cosentyx- secukinumab injection". DailyMed. 4 November 2022. Retrieved 9 November 2022.
  6. ^ a b c Cite error: The named reference Cosentyx EPAR was invoked but never defined (see the help page).